Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Nov;30(4):277-82.
doi: 10.3109/00207458608985678.

Open Label Evaluation of Cannabidiol in Dystonic Movement Disorders

Open Label Evaluation of Cannabidiol in Dystonic Movement Disorders

P Consroe et al. Int J Neurosci. .

Abstract

Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.

Similar articles

See all similar articles

Cited by 25 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback